What you see is (not) what you get

Citation for published version (APA):

de Jong, E. E. C., Hendriks, L. E. L., van Elmpt, W., Gietema, H. A., Hofman, P. A. M., De Ruysscher, D. K. M., & Dingemans, A-M. C. (2018). What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer. *Lung Cancer*, 123, 112-115.
<https://doi.org/10.1016/j.lungcan.2018.07.014>

Document status and date:

Published: 01/09/2018

DOI:

[10.1016/j.lungcan.2018.07.014](https://doi.org/10.1016/j.lungcan.2018.07.014)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer

Evelyn E.C. de Jong^{a,1}, Lizza E.L. Hendriks^{b,1}, Wouter van Elmpt^c, Hester A. Gietema^d,
Paul A.M. Hofman^d, Dirk K.M. De Ruyscher^c, Anne-Marie C. Dingemans^{b,*}

^a The D-Lab: Decision Support for Precision Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands

^b Department of Pulmonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, P. Debye laan 25, 6229 HX, Maastricht, The Netherlands

^c Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Doctor Tanslaan 12, 6229 ET, Maastricht, The Netherlands

^d Department of Radiology, Maastricht University Medical Center+, P. Debye laan 25, 6229 HX, Maastricht, The Netherlands

ARTICLE INFO

Keywords:

Non-small cell lung cancer
Contrast-enhanced computed tomography
Gadolinium-MRI
¹⁸F-FDG-PET
Image guidelines

ABSTRACT

Medical images are an integral part of oncological patient records and they are reviewed by many different specialists. Therefore, it is important that besides imaging experts, other clinicians are also aware that the diagnostic value of a scan is influenced by the applied imaging protocol.

Based on two clinical lung cancer trials, we experienced that, even within a study protocol, there is a large variability in imaging parameters, which has direct impact on the interpretation of the image. These two trials were: 1) the NTR3628 in which the added value of gadolinium magnetic resonance imaging (Gd-MRI) to dedicated contrast enhanced computed tomography (CE-CT) for detecting asymptomatic brain metastases in stage III non-small cell lung cancer (NSCLC) was investigated and 2) a sub-study of the NVALT 12 trial (NCT01171170) in which repeated ¹⁸F-fluorodeoxyglucose positron emission tomography (¹⁸F-FDG-PET) imaging for early response assessment was investigated.

Based on the problems encountered in the two trials, we provide recommendations for non-radiology clinicians, which can be used in daily interpretation of imaging. Variations in image parameters cannot only influence trial results, but sub-optimal imaging can also influence treatment decisions in daily lung cancer care, when a physician is not aware of the scanning details.

1. Introduction

Medical imaging is an essential component of the diagnostic procedures performed in lung cancer. Next to that, it is also used for response assessment. The imaging modalities used in oncology have evolved from simple X-rays to computed tomography (CT)- and magnetic resonance imaging (MRI) scans. Nuclear imaging has innovated by the introduction of positron-emission tomography (PET) with several tracers being ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) most frequently used. An ¹⁸F-FDG-PET-scan using an integrated PET-CT scanner combined with a contrast enhanced CT (CE-CT) is nowadays a standard staging technique in thoracic oncology. Due to ongoing technological innovations,

the sensitivity and specificity of these modalities have significantly improved. However, many factors, as patient preparation, image acquisition and reconstruction parameters affect the quality and accuracy of all these exams [1].

Images are nowadays an integral part of electronic patient records and can be reviewed directly by many different health care specialists. Consequently, it is important that besides the imaging experts (i.e. radiologists and nuclear medicine physicians), other reviewing clinicians are aware that the diagnostic value of a scan is influenced by the applied imaging protocol and can recognize common artifacts (e.g. breathing artifacts). More knowledge on this topic will provide clinicians tools to communicate with their imaging colleagues to prevent

* Corresponding author.

E-mail addresses: e.dejong@maastrichtuniversity.nl (E.E.C. de Jong), lizza.hendriks@mumc.nl (L.E.L. Hendriks), wouter.vanelmpt@maastro.nl (W. van Elmpt), hester.gietema@mumc.nl (H.A. Gietema), paul.hofman@mumc.nl (P.A.M. Hofman), dirk.deruyscher@maastro.nl (D.K.M. De Ruyscher), a.dingemans@mumc.nl (A.-M.C. Dingemans).

¹ Equal contribution.

image misinterpretation and to select the appropriate image acquisition protocol.

In two recently performed clinical trials (NTR3628 and NCT01171170) studying patients with non-small cell lung cancer (NSCLC) we experienced that, even though specific imaging guidelines were mandated by the trial protocol, there was a large variability in imaging parameters. This influenced not only the outcome of the trial but could also have impact on treatment by their clinical physician (medical oncologist/pulmonologist). In this manuscript, we describe the imaging problems encountered in these two trials. Furthermore, we will provide recommendations to guide clinicians in the interpretation of medical imaging based on our experience. Our goal is that this will result in improved clinical care as well as imaging standardization, not only in future multicenter studies, but also in daily clinical care.

2. Methods

2.1. NVALT12 ^{18}F -FDG PET/CT imaging sub-study

In all lung cancer patients eligible for therapy with curative intent, not only a CE- chest-CT, but also a whole body ^{18}F -FDG-PET is recommended [2,3]. The ^{18}F -FDG-PET, performed with a non-diagnostic low dose CT (LD-CT) for attenuation correction can be extended by an additional diagnostic CE-CT of the chest (with or without the upper abdomen and brain).

In the multicenter randomized phase II NVALT12 trial (NCT01171170) chemo-naïve patients with stage IV non-squamous NSCLC were treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. For patients in whom an ^{18}F -FDG-PET at baseline was performed as part of standard work-up, a second study ^{18}F -FDG-PET was performed within three weeks after start of treatment. The two ^{18}F -FDG-PETs were used for response assessment, and results have been reported [4]. It was assumed that image acquisition was per the European Association of Nuclear Medicine (EANM) guidelines for tumor imaging version 1 as introduced in 2009, therefore no PET guidelines were added to the protocol [1].

2.2. Study NTR3628: brain imaging

Although patients with brain metastases often have neurological complaints, 3–21% of neurologically asymptomatic patients with otherwise stage I–III lung cancer are diagnosed with brain metastases

on MRI [5]. This diagnosis is especially important in patients that are potentially eligible for therapy with curative intent. A post-gadolinium-MRI (post-Gd-MRI) is the imaging modality of choice, but when MRI is contra-indicated or too difficult to arrange within a reasonable time scale, a diagnostic CE-CT is an acceptable alternative [2,3]. Except for the recommendation to include Gd-contrast series, no recommendations are given in the ESMO and NCCN lung cancer guidelines regarding the minimal requirements for this brain MRI (e.g. applied MRI sequences (e.g. T1, T2 FLAIR, diffusion weighted imaging) and minimum contrast amount) [2,3]. For brain CTs, intravenous administration of iodine-containing contrast is advised but otherwise no recommendations are made (e.g. minimum number of mAs and minimum contrast dose) [2,3].

In the multicenter NTR3628 study, the additional value of a post-contrast brain MRI was evaluated in stage III (based on ^{18}F -FDG-PET/CE-CT) NSCLC patients. All patients underwent a dedicated brain CE-CT as part of the staging whole body ^{18}F -FDG-PET as standard of care [6]. Imaging requirements were: a standard ^{18}F -FDG-PET/CE-CT protocol that included a diagnostic CE-CT brain, and a 1.5T Gd-MRI brain (1 mm slices, 0.1 mmol/kg gadolinium), with a magnetization transfer contrast (MTC) pre-pulse to increase sensitivity and an additional post-contrast FLAIR sequence. MRI parameters were as recommended by an experienced neuro-radiologist (PH) and followed the American College of Radiology Appropriateness Criteria (ACR AC) [7]. After inclusion of all patients, CE-CTs and MRIs were per protocol centrally reviewed by PH for protocol adherence and presence of brain metastases.

3. Results

3.1. NVALT12 ^{18}F -FDG PET/CT imaging sub-study

In the imaging analysis sub-study of the NVALT12, 167 baseline scans and 118 follow-up PET scans for response evaluation were present. Only 97 (34%) of the 285 ^{18}F -FDG-PETs performed in this study had an ^{18}F -FDG uptake time as recommended by the EANM. Fifty-four (19%) scans had both uptake times in agreement with the uniform protocols for imaging in clinical trials (UPICT) guidelines. Supplementary material S1 shows the uptake times of the baseline- and the response scans ranked in ascending order for the baseline scan, only the uptake times between the red lines can be used for response assessment. The other investigated parameters in this imaging sub-study, correction factors (attenuation, randoms, scatter) and reconstruction

Fig. 1. a) Baseline ^{18}F -FDG-PET/CT scan of the NCT01171170 trial; b) Response ^{18}F -FDG-PET/CT scan of the same patient, showing that a different SUV_{mean} of the liver can lead to a visually underestimation of response in the tumor; c) Axial CT image of the brain of the NTR3628 after contrast administration, reconstructed with a field of view of 500 × 500 mm with raised arms (note the high level of noise and the streak artifacts due to beam hardening); d) Axial CT image of the brain of the same patient at approximate the same level, also after contrast administration, reconstructed with a FOV of 200 × 200 mm with the arms lowered. The window and level setting are identical as well as other acquisition parameters for all imaging, note the difference in image quality.

Table 1

Recommendations and consequences for a quality check of repeated ^{18}F -FDG-PET scans, brain CE-CT scans and brain MRI scans based on current guidelines, expert opinion and results of two clinical trials.

Image Modality	Recommendations	Consequences when not performed
MRI brain	T2	Combination of sequences gives a complete overview, missing a sequence can lead to a wrong diagnosis (e.g. benign vs. malignant)
	T2-FLAIR	
	DWI	
	T1 before contrast	
	T1 post contrast	
CE-CT brain	Axial slice thickness between 3 mm and 5 mm	With thicker slices small lesions can be missed
	Minimal 1.5 T	Too low signal-noise ratio and lower resolution can lead to missing small lesions.
	Field-of-view should be set to head	Artefacts
	Arms of the patients at thorax level	Artefacts
	Delayed imaging	Less contrast in the head
^{18}F -FDG-PET/CT	Higher contrast dose	Lesion less visible
	Identical scanner	Different acquisition parameters
	Patient position similar to baseline scan	Difficult measuring same region of interest
	Identical PET acquisition repeated scans	Different spatial resolution, different SUV values
	Identical PET reconstruction repeated scans	Different spatial resolution, different SUV values
	Uptake times > 55 min; < 75 min	Lower, higher SUV values
	Δ uptake times between repeated scans < 15 min	SUV value deviations
	DICOM header/CRF contains: injection time, scan time, patient weight, radionuclide dose, SUV conversion tag	SUV value cannot be calculated
	Mean SUV liver between 1.3 and 2.5	Misleading visual interpretation

If any of the recommendations is not met, please consult your nuclear medicine or radiology expert.

settings (method, convolution kernel, matrix size) were assessed in a quality score.

In this study, 60% (171/285) of the ^{18}F -FDG-PETs had a SUV_{mean} of the liver within reference values. Fig. 1 shows an example of how a difference in SUV_{mean} of the liver between the baseline and the response scan can lead to a visual underestimation of tumor response. Although we expected a non-compliant SUV_{mean} of the liver for scans with a low quality score, our results did not show such a relation between the quality score and SUV_{mean} of the liver [8].

3.2. Study NTR3628: brain imaging

With respect to dedicated brain imaging, imaging related problems were encountered both during set-up and after central imaging review. Trial set-up was in 2012 and it was planned to have four hospitals involved, but one did not have a MRI scanner that could meet the required technical standards and was excluded from participation. Two other hospitals used MRI protocols that did not meet the required standards (5 mm instead of 1 mm slices, no MTC technique), but they agreed to update their protocols to be able to participate in the study. Two-hundred-fifteen neurologically asymptomatic, extracranial stage III (based on the ^{18}F -FDG-PET-CE-CT) NSCLC patients were included between December 2012 and July 2016. After central review, it turned out that in 56 patients (26%) the CE-CT of the brain did not meet the criteria for a dedicated brain imaging protocol. Remarkably, for these patients CE-CT brain results were reported in the radiology report without noting the limitations of the study. Problems with these brain CE-CTs were the field of view (FOV), adjusted to the thorax, but not to the brain) and the arm position (above the head instead of at thorax level, see Fig. 1).

4. Discussion

Imaging techniques have significantly evolved over the last years and have become more sensitive for the detection of subtle abnormalities. In (lung) cancer guidelines, recommendations regarding imaging techniques are made and even separate detailed ^{18}F -FDG-PET-(CT) recommendations exist [2,3]. However, no recommendations are made on the minimal technical requirements, resulting in a large variation in accuracy. Therefore, there is a large variability in imaging parameters and scanners, which can influence not only the clinical trial outcome

but also the clinical interpretation by the treating physician. In this manuscript, we report on two trials in which problems were encountered due to variation in applied imaging protocols, which people did not realize beforehand. In NTR3628, after central imaging review, it turned out that the CE-CTs brain of several included patients suffered from unreported serious flaws. In this specific trial, the non-diagnostic CE-CT had no clinical consequences, as all patients underwent a post-Gd-MRI. However, when limitations of an examination are not recognized nor reported, this can have serious consequences (see Table 1). Depending on geographical location and institution, in 48–62% of patients a CE-CT is performed instead of a post-Gd-MRI to screen for brain metastases [9]. Although not reported in CE-CT imaging guidelines, is the importance of the patient position: it should be reproducible and standardized, and it matters what the FOV and patient position is. The FOV should be adjusted to the size of the head and arms should be at thorax level to reduce artifacts and acquire diagnostic images (see Fig. 1). Furthermore, just the application of iodine contrast administration does not make the CT-brain diagnostic: timing of the scan relative to contrast injection and the amount of contrast material injected are important. For tumor response assessment using ^{18}F -FDG-PET, it is important that scans are performed with the same acquisition and reconstruction settings as baseline. Because varying uptake times lead to variations in measured SUV, a larger uptake time will result in a higher SUV because tumor SUV increases over time. In response assessment studies, changes in SUV over time are the parameter of interest and therefore differences in uptake times between repeated scans can lead to scan misinterpretation. Variability in uptake times of the baseline as well as the response scan made that only 46 scans could be used for early response assessment in the NVALT12 sub-study. A study of Kuhnert et al. [10] showed that for settings like the injected activity and the uptake time the SUV_{mean} of the liver could be used for quality assessment in compliance with the EANM guideline. This means that in the NVALT12 sub-study the large variability in SUV_{mean} of the liver is most probably caused by the differences in uptake time (although a treatment effect cannot be excluded). In the NVALT12 sub-study no relation between deviation in image parameters, reflected in the quality score, and the SUV_{mean} of the liver was reported. The SUV_{mean} of the liver can therefore not exclude all quality issues, although, it could be used as a quick quality control with reference values between 1.3 and 2.5. Our recommendations for clinicians regarding repeated ^{18}F -FDG-PET imaging for response assessment are to try to use the same

scanning parameters as for the first scan, or check if the same scan parameters are used as in the previous scan. Scans with an uptake time less than 55 min or more than 75 min cannot reliably be used and checking the SUV_{mean} of liver can be used as quality assurance. For data analysis it is important that all scan parameters are noted in the DICOM header, but at least injection time, scan time, patient's body weight, radionuclide dose and the SUV conversion tag should be present. An example of a DICOM header with the minimum required tags is shown in the supplementary material S2. For brain CE-CT combined with the ^{18}F -FDG-PET scan, we recommend that the clinician checks the head FOV, the patient arm position and the contrast dose and timing.

For MRI, at least a T2-weighted sequence, a T2-FLAIR and a T1-weighted sequence pre- and post-contrast should be performed. See for an overview of these recommendations Table 1. If any of the recommendations cannot be met it is advised to consult an imaging expert.

In addition, radiologists need to be informed about the indication for the requested scan and therefore clinicians must provide all clinical information that is important to determine the optimal imaging protocol to apply. Next to that, for non-imaging clinicians it is important to evaluate whether the applied imaging protocol is indeed adequate for the requested purpose. Our quality recommendations will potentially lead to a more uniform clinical interpretation and could be helpful during multidisciplinary meetings. These recommendations should preferably be tested prospectively.

Funding

This work was supported by the Dutch Cancer Society (grant UM 2010-4883).

Disclosure

Author AD is advisory board member of Roche, Eli Lilly, Astra Zeneca, MSD and Pfizer. Author LH is advisory board member of

Boehringer-Ingelheim and MSD. All remaining authors have declared no conflicts of interest.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.lungcan.2018.07.014>.

References

- [1] R. Boellaard, M.J. O'Doherty, W.A. Weber, et al., FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0, *Eur. J. Nucl. Med. Mol. Imaging* 37 (1) (2010) 181–200.
- [2] P.E. Postmus, K.M. Kerr, M. Oudkerk, et al., Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up, *Ann. Oncol.* 28 (suppl. 4) (2017) iv1–iv21.
- [3] D.S. Ettinger, D.E. Wood, D.L. Aisner, et al., Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology, *J. Natl. Compr. Cancer Netw.* : JNCCN 15 (4) (2017) 504–535.
- [4] E.E. de Jong, W. van Elmpt, R.T. Leijenaar, et al., [^{18}F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches, *Eur. J. Nucl. Med. Mol. Imaging* 44 (Jan. (1)) (2016) 8–16 Epub 2016 Sep 6.
- [5] M.M. Hochstenbag, A. Twijnstra, P. Hofman, E.F. Wouters, G.P. ten Velde, MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? *Lung Cancer (Amsterdam Neth.)* 42 (2) (2003) 189–193.
- [6] J. Schoenmaekers, L.E. Hendriks, P. Hofman, et al., Screening for brain metastases in patients with stage III NSCLC, MRI of CT? A prospective study, *J. Thoracic Oncol.* 12 (S1) (2016) MA06.05.
- [7] ACR-ASNR-SPR. ACR-ASNR-SPR Practice Parameter for the Performance and Interpretation of Magnetic Resonance Imaging (MRI) of the Brain, (2013) <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/mr-brain.pdf?la=en>.
- [8] E.E.C. de Jong, W. van Elmpt, O.S. Hoekstra, et al., Quality assessment of positron emission tomography scans: recommendations for future multicentre trials, *Acta Oncol. (Stockholm Sweden)* 56 (11) (2017) 1459–1464.
- [9] B.J. Hudson, M.B. Crawford, J.J. Curtin, Brain imaging in lung cancer patients without symptoms of brain metastases: a national survey of current practice in England, *Clin. Radiol.* 70 (6) (2015) 610–613.
- [10] G. Kuhnert, R. Boellaard, S. Sterzer, et al., Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis, *Eur. J. Nucl. Med. Mol. Imaging* 43 (2) (2016) 249–258.